TI 385
Alternative Names: TI-385Latest Information Update: 23 Aug 2023
At a glance
- Originator TeraImmune
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research B-cell lymphoma
Most Recent Events
- 17 Oct 2022 Early research in B-cell lymphoma in USA (Parenteral) (Teraimmune pipeline, October 2022)